secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTERPACE BIOSCIENCES, INC. (IDXG)
CIK:        0001054102
Form:       8-K
Filed at:   2022-10-04T23:59:59+00:00
Accession:  0001493152-22-027554
Event type: leadership
Sentiment:  negative
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Interpace Biosciences CFO Thomas Freeburg resigns; continues as consultant and principal financial officer
--------------------------------------------------------------------------------

- CFO Thomas Freeburg resigned effective Sept 30, 2022; will serve as consultant and acting principal financial officer until new CFO hired.
- Severance of $127,500 (six months' base salary) payable over six months; equity awards scheduled to vest in 24 months fully accelerated.
- Consulting fee of $6,000/month for up to 20% time (~8 hrs/week); term from Sept 30, 2022 to Jan 30–Mar 30, 2023.
- Health and dental benefits continued for six months at Company expense; COBRA eligibility if elected.
- Company actively recruiting a replacement CFO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1054102/000149315222027554/0001493152-22-027554-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1054102/000149315222027554/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-027554

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer